HC Wainwright Has Bullish Outlook for UNCY FY2024 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – HC Wainwright lifted their FY2024 EPS estimates for shares of Unicycive Therapeutics in a research note issued on Thursday, November 14th. HC Wainwright analyst E. Arce now forecasts that the company will post earnings of ($0.11) per share for the year, up from their prior estimate of ($0.12). HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ FY2025 earnings at ($0.34) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at $0.02 EPS and FY2028 earnings at $0.53 EPS.

Separately, Benchmark restated a “speculative buy” rating and issued a $3.00 price objective on shares of Unicycive Therapeutics in a research report on Friday, September 6th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Unicycive Therapeutics currently has an average rating of “Buy” and an average target price of $5.13.

Unicycive Therapeutics Price Performance

NASDAQ:UNCY opened at $0.46 on Monday. The business has a fifty day moving average price of $0.43 and a 200-day moving average price of $0.54. Unicycive Therapeutics has a one year low of $0.20 and a one year high of $1.82. The firm has a market capitalization of $47.75 million, a price-to-earnings ratio of -0.47 and a beta of 2.29.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd purchased a new stake in shares of Unicycive Therapeutics during the 3rd quarter worth $29,000. Walleye Capital LLC acquired a new position in shares of Unicycive Therapeutics during the third quarter valued at about $2,040,000. Acuta Capital Partners LLC purchased a new position in shares of Unicycive Therapeutics in the third quarter worth $807,000. Great Point Partners LLC purchased a new position in Unicycive Therapeutics in the 3rd quarter worth $3,491,000. Finally, Bleakley Financial Group LLC purchased a new stake in Unicycive Therapeutics in the third quarter valued at approximately $33,000. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.